Trial
NCT04470622
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Heron Therapeutics
Collaborators
—
Condition
COVID-19
Intervention
Aprepitant injectable emulsion
Why stopped
Study was terminated early by Heron, and was not terminated for safety reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-02